Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
Authors Sacchi M, Villani E, Nucci P
Received 31 March 2014
Accepted for publication 1 April 2014
Published 15 September 2014 Volume 2014:8 Pages 1855—1858
Checked for plagiarism Yes
Matteo Sacchi, Edoardo Villani, Paolo Nucci
University Eye Clinic, San Giuseppe Hospital, University of Milan, Milan, Italy
We read with interest the article entitled "Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma" by Inoue et al.1 In this study, the authors reported the efficacy of tafluprost in naïve patients with normal-tension glaucoma (NTG) over 3 years of follow-up.
The intraocular pressure (IOP)-lowering efficacy of tafluprost in NTG has been recently reported by Mizoguchi et al2 and Nakano et al.3
Whereas tafluprost is available in Europe in a preservative-free formulation, the three aforementioned studies1–3 were all carried out in Japan, where tafluprost is on the market as a benzalkonium chloride (BAK)-containing formulation.
View original paper by Inoue and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]